Can stopping losartan cause heart failure?

Can Stopping Losartan Cause Heart Failure?

Stopping losartan does not directly cause heart failure, but abrupt discontinuation in patients with existing heart failure with reduced ejection fraction (HFrEF) significantly increases the risk of death and rehospitalization. 1

Risk of Discontinuation in Heart Failure Patients

The most critical evidence comes from the 2022 AHA/ACC/HFSA guidelines, which clearly demonstrate that withdrawal of ACE inhibitors or ARBs (like losartan) in hospitalized patients with HFrEF is associated with higher rates of post-discharge mortality and readmission 1. This finding from the Get With The Guidelines-Heart Failure (GWTG-HF) registry represents real-world data showing concrete harm from stopping these medications.

Key points about discontinuation:

• Discontinuation of any oral guideline-directed medical therapy (GDMT) in HFrEF patients was associated with higher mortality risk 1
• The harm occurs specifically in patients who already have heart failure, not in those taking losartan solely for hypertension
• The mechanism is loss of renin-angiotensin system blockade, leading to increased afterload, fluid retention, and cardiac remodeling

Context: Who Is at Risk?

The risk applies specifically to:

• Patients with heart failure with reduced ejection fraction (HFrEF) - those with weakened heart muscle
• Patients taking losartan as part of their heart failure treatment regimen
• Hospitalized heart failure patients where discontinuation during acute illness carries particularly high risk

For Hypertension Patients Without Heart Failure

In patients taking losartan only for hypertension without underlying heart failure:

• Stopping losartan will not cause new-onset heart failure
• Blood pressure may rise, which over time could contribute to cardiac stress
• The FDA label notes losartan reduces cardiovascular events including stroke by 25% compared to atenolol in hypertensive patients with left ventricular hypertrophy 2

Clinical Implications and Warnings

The 2022 guidelines explicitly state that oral GDMT should not be withheld for mild or transient reductions in blood pressure or mild deteriorations in renal function 1. True contraindications are rare.

The 2025 European Heart Failure Association consensus reinforces that low blood pressure should not be a barrier to continuing ARB therapy, as patients with lower baseline blood pressure (95-110 mmHg) often experience blood pressure increases with continued treatment, likely reflecting improved cardiac function 3.

Common Pitfalls to Avoid:

• Do not stop losartan in HFrEF patients due to mild hypotension - the benefits outweigh risks 1, 3
• Do not discontinue during hospitalization for heart failure unless true contraindications exist (cardiogenic shock, angioedema) 1
• Do not assume lower doses are safer - the HEAAL trial showed 150 mg losartan was more effective than 50 mg in reducing death or heart failure hospitalization (43% vs 46%, p=0.027) 4

Bottom Line Algorithm:

For patients WITH heart failure:

• Continue losartan unless absolute contraindication
• Stopping increases mortality and rehospitalization risk
• Titrate to maximum tolerated dose (ideally 100-150 mg daily) 4

For patients WITHOUT heart failure (hypertension only):

• Stopping will not cause heart failure
• Blood pressure control will be lost
• Consider alternative antihypertensive if discontinuation necessary